Company Tissue Regenix Group plc

Tissue Regenix Group plc is a medical device company in regenerative medicine. The principal activity of the Company is the exploitation of platform technologies in the field of bone graft substitutes and soft tissue. It is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. Its divisions include dCELL, BioRinse and GBM-V. The Company's patented decellularization technology (dCELL) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Its proprietary BioRinse technology platform is primarily utilized to provide sterile tissue prepared in a manner to minimize the negative effects of processing. GBM-V produces tissue preparations for ophthalmology, primarily cornea, using conventional, classical methods.

Number of employees: 82